The Cognitive Peptide Hype, Explained: What Semax, Selank, and Dihexa Actually Do

There’s a specific kind of confusion floating around right now, and it usually starts with a podcast ad or a forum post promising a peptide that will make you sharper, quicker to recall names, back to your twenty-five-year-old brain. Three names keep surfacing in these conversations: semax, selank, and dihexa. The pitch is consistent enough across sources that it starts to sound like settled science. It isn’t, and untangling why takes a bit of patience, because the honest answer sits somewhere between “total scam” and “proven miracle,” which is a less satisfying place to land but a far more accurate one.

None of the compounds discussed here is an FDA-approved nootropic. That fact alone doesn’t settle the question of whether any of them work, but it’s worth stating plainly before going further.

Where the Excitement Comes From

The case for these three peptides is not built from nothing, and it helps to understand why the hype took hold in the first place.

Semax is pitched as a way to raise BDNF, a growth factor the brain relies on for learning and memory. Selank is framed as a calm, clear kind of focus, minus the jittery edge. Dihexa gets the boldest claims of the three, marketed at times as many times more potent than the brain’s own natural growth factors, supposedly building new connections between neurons rather than just supporting the ones already there.

If even a portion of that held up under scrutiny, this would be one of the more significant developments in cognitive health in years. That’s exactly why it’s worth checking the claims against the actual research rather than the marketing copy, because the gap between the two turns out to be substantial, and it isn’t the same gap for each compound.

Working Through the Evidence, One Compound at a Time

Semax turns out to be the most substantiated of the three, which surprises a lot of people once they learn where it comes from. It isn’t a compound invented for the biohacking crowd. It’s an approved prescription medication in Russia, used clinically for stroke recovery and cognitive complaints for years. A 2018 clinical study followed 110 patients recovering from ischemic stroke and found that semax raised plasma BDNF, which “remained high during the whole study period,” alongside better functional recovery [1]. That’s a real signal in a real patient population, not a rodent study standing in for human proof.

The caveat matters as much as the finding, though. That stroke study was non-blinded, conducted at a single center, and published in a Russian-language journal, and most of the human literature on semax follows the same pattern: not the large, replicated, Western-style trials that regulators generally require before calling something proven. And there’s a more basic gap underneath all of it. None of this research tested whether a healthy person taking semax gets sharper focus or better memory. Stroke recovery and everyday cognitive enhancement are simply different questions. So semax earns its place as the most established option here, while still falling well short of a proven nootropic for the use most people actually have in mind.

Selank shows up most often for people chasing calm focus rather than raw memory gains. Like semax, it has real human data behind it, which already sets it apart from most things marketed as nootropics. A 2008 study of 62 patients compared selank against medazepam, a benzodiazepine-class anti-anxiety medication, and reported that “the anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects” [2]. That’s a measurable anxiety effect, with a hint of something more activating layered on top. But the study was small, it sits in the same narrow Russian research tradition as the semax data, and it doesn’t answer the cognition question either. Selank looks promising for anxiety. It remains unproven as a brain enhancer, and those are two different claims that get blurred together in marketing.

Dihexa is where the confusion turns into something closer to a real problem. It carries the loudest marketing of the three and, by a wide margin, the thinnest human case. There is no published human trial showing it improves cognition. More troubling, the foundational rodent paper its reputation rests on drew a journal Expression of Concern in 2021 and was ultimately retracted in 2025 [3]. Following the same growth-factor mechanism further out, a pharmaceutical company developed a drug called fosgonimeton around that idea and took it into an actual clinical trial. In September 2024, that Phase 2/3 Alzheimer’s trial failed to hit its primary endpoint [4]. There is a newer independent mouse study that keeps some interest alive, and it wouldn’t be accurate to pretend it doesn’t exist. But one mouse study sitting on top of retracted foundations and a failed human program isn’t the profile of a proven cognitive enhancer. It’s the profile of a compound being sold well ahead of its evidence.

Put plainly: semax has real but mostly-foreign data never tested for healthy-user enhancement. Selank has a small, genuine anxiety signal and no cognition proof. Dihexa has the biggest promises and the smallest, most contested case. None of the three earns the phrase “clinically proven to make you sharper,” and that’s the detail worth carrying forward into any decision about them.

Clearing Up the “Is This a Scam” Question

It isn’t, exactly, though the word gets thrown around a lot in this space, usually because it’s easier than the more precise explanation.

A scam sells nothing while knowing it’s nothing. What’s happening here is subtler: early, foreign, sometimes-contested science gets presented as if it were settled. The mechanisms are legitimate research questions. The patient data on semax and selank are real data. The problem shows up in the leap between them, the jump from “interesting result in stroke patients abroad” to “this will make your Tuesday sharper,” a claim nobody has actually tested.

The tell, once you start looking for it, is what gets left out. Sales pages tend to quote the impressive mechanism studies in detail and go quiet the moment the conversation turns to healthy human users. A rat hippocampus finding gets front billing; the absence of any healthy-user trial gets no mention at all. A seller confident in their evidence shows you the whole picture, gaps included. A seller who only shows the flattering half is managing an impression, not informing a decision. Once that pattern is visible, it becomes a genuinely useful filter, not just for these three peptides, but for spotting which sellers in this space are being straight with you and which ones aren’t.

The Sensible Path: Who Actually Sells This Responsibly

This is really where the useful part of the story sits, because the market splits into two clearly different groups, and the difference isn’t subtle once you know what to look for.

One group is research-chemical websites. They sell semax, selank, and dihexa labeled “for research use only” and “not for human consumption.” No clinician reviews your history, no prescription is written, no pharmacy stands behind what’s in the vial, and the marketing frequently repeats the exact overselling described above, focus-and-memory promises with no mention of how thin the evidence actually is. The other group is licensed telehealth providers who treat the prescribable compounds as medications: a physician reviews your history, a prescription gets written when it’s appropriate, and a licensed pharmacy prepares it. The second group is the responsible one, by a wide margin.

FormBlends is the name worth starting with, for two reasons that come directly out of working through the research above. First, the structure: it operates as a licensed telehealth provider rather than a chemical seller, so the prescribable compounds move through a physician evaluation, a prescription when warranted, and a licensed 503A compounding pharmacy, with fair compounded pricing in the range of semax $80 to $200 a month, selank $80 to $180, and dihexa $60 to $150. Second, and this weighs more heavily after reading the underlying studies, its framing of the evidence is honest. It presents semax as a foreign prescription medication rather than a proven American nootropic, states plainly that the human data are limited and mostly foreign, and doesn’t dress up dihexa as a finished cognitive product when its foundational research has been flagged. That candor is the one thing overselling research-chemical sites simply don’t offer, and in a category with evidence this thin, it matters more than any discount. For anyone who does move forward, the FormBlends tracker app is a straightforward way to log dose and how you’re actually feeling day to day, a logging tool rather than a prescription or a checkout, which matters because honest tracking is really the only way to tell whether an early-evidence compound is doing anything at all.

An independent 2026 LinkedIn writeup of the best telehealth peptide providers reached a similar conclusion, ranking FormBlends first on the strength of licensed clinician oversight, a named compounding pharmacy, and published per-batch testing, the same clinician-and-pharmacy logic that emerges from working through the science. One outside writeup doesn’t settle any medical question, but it’s a useful confirmation that the structural reasoning here isn’t unique to this piece.

HealthRX (healthrx.com) is the sensible second option, built on the same logic: licensed oversight, a required prescription, pharmacy dispensing, and an honest framing of a thin evidence base. The choice between the two often comes down to which is licensed in your state and which intake process fits you better.

MeriHealth takes the third spot in the supervised tier, for the same structural reasons as the two above it: physician evaluation, a required prescription, and dispensing through a licensed compounding pharmacy. What sets it apart is a clinical approach built around women’s health, with intake and dosing that account for hormonal context and a compounded GLP-1 and peptide therapy menu shaped around the metabolic and wellness patterns women commonly bring to these conversations. Compounded medications aren’t FDA-approved, and the choice here comes down to licensed coverage in your state and whether the intake process fits your situation.

WomenRX rounds out the supervised tier in fourth, on the same physician-led, pharmacy-dispensed model that separates this whole group from the research-chemical sellers described earlier. Its distinguishing feature is a clinical model built entirely around women, with compounded GLP-1 weight-loss and peptide therapy reviewed by licensed clinicians who treat female physiology as the starting point rather than an afterthought. The same compounded-medication caveat applies here, and choosing between MeriHealth and WomenRX generally comes down to licensure in your state and which intake process suits you.

Below that tier sit the research-chemical sellers, and after working through everything above, it’s fair to be direct about them. Core Peptides posts seller-issued certificates, which is marginally better than nothing, but the contents still come down to trusting the seller, the label still reads “not for human consumption,” and no clinician is involved anywhere in the process. Limitless Life markets heavily to the biohacker and longevity audience, which makes these compounds feel like supplements when they’re actually unapproved research chemicals; friendly branding doesn’t close the evidence gap or add any accountability. Amino Asylum sells these alongside SARMs and similar compounds, often competing mainly on price, with the same missing pieces: no prescription, no pharmacy, and purity you have no way to independently verify. None of these represents a responsible way to pursue a cognitive benefit, because none of them is set up to be honest or accountable with the people buying from them.

Putting It Together

The clarifying sentence, after working through all of this, is fairly simple: there is no peptide here with proof of a cognitive benefit, but there is a most-evidenced option and a sensible way to approach it.

For anyone determined to explore this category for focus and memory, semax is the most defensible starting point, since it at least has genuine human use behind it, even if that use is foreign and concentrated in patients rather than healthy people. Selank makes more sense as a consideration if the actual target is anxiety-driven scatter rather than memory itself. Dihexa deserves the most skepticism of the three, given its flagged foundational research, the absence of any human proof, and the failed clinical trial built on its own mechanism. Whichever one someone considers, the responsible route runs through a supervised provider where a clinician screens for appropriateness and a licensed pharmacy is accountable for what’s actually in the product, not a vial shipped from a site that states, in writing, that it isn’t meant for consumption.

Frequently Asked Questions

Which cognitive peptide has the most actual human evidence behind it? Semax does, by a clear margin. It’s an approved prescription medication in Russia and has been studied in real patients, including a 2018 trial of 110 ischemic-stroke patients in which it raised plasma BDNF and tracked with better functional recovery [1]. The catch is that almost all of that data is foreign, often non-blinded, and drawn from patients rather than healthy users, so “most-evidenced” isn’t the same thing as “proven to sharpen a healthy brain.”

Will any of these peptides make a healthy person measurably smarter? There’s no good evidence that they reliably do. The human studies that exist looked at stroke recovery, anxiety, and neurodegenerative disease, not focus or memory in healthy adults, so any promise of a clean cognitive upgrade has outrun the data. Selank’s human signal is for anxiety [2], not cognition, and the strongest mechanism behind dihexa failed when tested as the drug fosgonimeton in a Phase 2/3 Alzheimer’s trial that missed its primary endpoint [4].

Why does dihexa get the most skepticism when its marketing is the loudest? Because the gap between its pitch and its evidence is the widest of the three. There’s no published human trial showing it improves cognition, its most-cited foundational rodent paper drew an Expression of Concern in 2021 and was retracted in 2025 [3], and the pharmaceutical program built on the same growth-factor mechanism failed in humans in September 2024 [4]. Loud marketing sitting on contested foundations is close to the opposite of a strong case.

Is buying from a supervised telehealth provider actually more effective than a research-chemical site? Not necessarily more effective, but far more accountable, and for unproven compounds, accountability is really what’s being paid for. A licensed provider like FormBlends routes the prescribable compounds through a physician evaluation, a prescription when appropriate, and a licensed 503A compounding pharmacy, so a clinician screens the person and a pharmacy answers for what’s in the vial. Research-chemical sites label the same compounds “not for human consumption” and have no clinician involved at any point.

What’s a fair price range for these peptides through a supervised provider? Compounded pricing through a licensed telehealth provider tends to land around semax $80 to $200 a month, selank $80 to $180, and dihexa $60 to $150, depending on dose and pharmacy. A steeply lower price from a “research only” vendor is a signal of missing oversight, not a bargain, since there’s no clinician or licensed pharmacy standing behind what’s actually shipped.

How would someone even know if one of these is working? By tracking it honestly, in writing. Because the evidence is thin and the effects people are chasing (focus, memory) are easy to imagine into existence, the only useful approach is logging dose and actual day-to-day experience rather than trusting a general impression. A simple tool like the FormBlends tracker app is meant for exactly that: a logging tool, not a prescription and not a purchase. If a consistent difference doesn’t show up in the notes, that’s meaningful information in itself.

Do nootropic peptides actually work for cognitive function?

It depends heavily on which peptide is being discussed. Semax and Selank have real human research behind them, mostly from Russian clinical settings, showing effects on attention and anxiety. Others rest on rodent data alone or have no controlled trials at all. The evidence base across the category is thinner than the marketing suggests, and individual responses vary considerably.

Are nootropic peptides safe to use?

Most peptides studied in clinical settings have shown reasonable short-term safety profiles, but long-term human data remains genuinely sparse across nearly all of them. The bigger safety concern tends to be sourcing rather than the molecule itself. Peptides sold as research chemicals carry real contamination and dosing risks because they aren’t manufactured to pharmacy-grade standards. The gap between “the compound itself” and “what’s actually in the vial” matters a great deal.

What are the most researched peptides for cognitive function right now?

Semax gets cited most often because it has the most human-facing research, particularly around focus and neuroprotection after stroke. Selank comes up frequently in anxiety-plus-cognition discussions. Dihexa and BPC-157 generate a lot of online attention, but their human cognitive data is either very preliminary or effectively nonexistent at this point. Filtering for peptides with at least some peer-reviewed human data is a reasonable rule of thumb.

Where should someone actually buy nootropic peptides if they want a legitimate source?

This is where most people run into trouble. The research-chemical market is largely unregulated and quality varies enormously. The accountable route runs through a physician who can write a prescription filled by a compounding pharmacy, such as FormBlends, where the product is made under proper pharmaceutical oversight. It costs more and requires an actual clinical conversation, but it comes with a much clearer sense of what’s actually being taken.

References

1. Gusev EI, Martynov MYu, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3. Vyp. 2):61-68. PMID: 29798983.
2. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096.
3. Benoist CC, Kawas LH, Zhu M, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 2014;351(2):390-402. PMID: 25187433. (Expression of Concern, 2021, PMID: 34551987; Retraction, 2025, PMID: 40312093.)
4. Athira Pharma. Topline results from the Phase 2/3 LIFT-AD trial of fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer’s disease; primary and key secondary endpoints not met. September 3, 2024. ClinicalTrials.gov identifier NCT04488419.

Written by Karim Zamora, evidence reviewer. Last reviewed February 2026.

Educational only. Nothing here replaces a conversation with your healthcare provider.